NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 71 resultados LastUpdate Última actualización 16/10/2019 [15:07:00] pdf PDF

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days

Página1 de 3 nextPage   por página


ANTIBODY-DRUG CONJUGATES AND THEIR USES FOR THE TREATMENT OF CANCER

NºPublicación: EP3552631A1 16/10/2019

Solicitante:

INATHERYS [FR]

Resumen de: EP3552631A1

The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to TfR, the transferrin receptor, and wherein the drug is preferably chosen among a cytotoxic drug. Such antibody-drug conjugates are useful in particular in treating proliferative diseases including cancers, such as lymphoma or leukaemia.

traducir

NEW INHIBITORS OF BONE RESORPTION

NºPublicación: EP3553061A1 16/10/2019

Solicitante:

CENTRE NAT RECH SCIENT [FR]
UNIV MONTPELLIER [FR]
AXLR SATT DU LANGUEDOC ROUSSILLON [FR]

Resumen de: EP3553061A1

The invention relates to a compound of formula (I):and its use as drug, in particular for use in prevention and/or treatment of disease-associated bone loss, preferably selected in the group consisting of bone metastases, multiple myeloma, osteoporosis, osteopenia due to bone metastases, osteogenesis imperfecta, periarticular erosions in rheumatoid arthritis, primary hyperparathyroidism, hypercalcemia of malignancy, Paget's disease of bone, periodontal disease, immobilization induced osteopenia, and glucocorticoid treatment.

traducir

METHODS OF DIAGNOSING AND TREATING AGGRESSIVE CUTANEOUS T-CELL LYMPHOMAS

NºPublicación: WO2019195769A1 10/10/2019

Solicitante:

BRIGHAM & WOMENS HOSPITAL INC [US]
OMALLEY JOHN T [US]

Resumen de: WO2019195769A1

Methods of identifying and treating subjects who are at risk of developing aggressive T-cell lymphomas, such as cutaneous T-cell lymphomas. The methods include determining the tumor clone frequency.

traducir

BCMA-CAR-T CELLS

NºPublicación: WO2019195017A1 10/10/2019

Solicitante:

PROMAB BIOTECHNOLOGIES INC [US]
FOREVERTEK BIOTECHNOLOGY CO LTD [CN]

Resumen de: WO2019195017A1

The present invention is directed to a monoclonal anti-human BCMA antibody, or a single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 7. The present invention is also directed to a BCMA chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The monoclonal antibody of the present invention exhibits selective and high-affinity binding to BCMA. BCMA CAR-T cells based on BCMA scFv of the present invention significantly decreases multiple myeloma tumor growth in an animal model.

traducir

PROTEINS

NºPublicación: US2019310255A1 10/10/2019

Solicitante:

OXFORD BIOTHERAPEUTICS LTD [GB]

Resumen de: US2019310255A1

The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.

traducir

CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF CANNABINOID RECEPTOR MODULATORS

NºPublicación: US2019308952A1 10/10/2019

Solicitante:

ARENA PHARM INC [US]

EP_3395812_A1

Resumen de: US2019308952A1

The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor and are therefore useful in the treatment of CB2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and Parkinson's disease.

traducir

TARGETING CHROMATIN REGULATORS INHIBITS LEUKEMOGENIC GENE EXPRESSION IN NPM1 MUTANT LEUKEMIA

NºPublicación: US2019307750A1 10/10/2019

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]

AU_2017212572_A1

Resumen de: US2019307750A1

Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.

traducir

Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof

NºPublicación: AU2018226884A1 10/10/2019

Solicitante:

F1 ONCOLOGY INC

CA_3054064_A1

Resumen de: AU2018226884A1

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

traducir

New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds

NºPublicación: AU2019232929A1 10/10/2019

Solicitante:

NUCANA PLC

JP_2017535587_A

Resumen de: AU2019232929A1

C:\Interwo n\NRPortbl\DCCSXD\19329517_l.docx-l9/09/2019 The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours inhomo sapiens. The compounds are derivatives of cordycepin (3'-deoxyadenosine) having a 2' and/or 5'-amino-acid ester phosphoramidate moiety.

traducir

CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMA

NºPublicación: US2019307797A1 10/10/2019

Solicitante:

MAAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ GEMEINSCHAFT [DE]

JP_2019527537_A

Resumen de: US2019307797A1

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

traducir

MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)

NºPublicación: AU2019232918A1 10/10/2019

Solicitante:

MIRAGEN THERAPEUTICS INC

US_2019106695_A1

Resumen de: AU2019232918A1

The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.

traducir

Azetidine derivative

NºPublicación: AU2018228555A1 10/10/2019

Solicitante:

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

WO_2018157820_PA

Resumen de: AU2018228555A1

Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma.

traducir

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

NºPublicación: US2019307745A1 10/10/2019

Solicitante:

RELAY THERAPEUTICS INC [US]
DE SHAW RES LLC [US]

WO_2018057884_PA

Resumen de: US2019307745A1

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.

traducir

ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHA

NºPublicación: US2019309077A1 10/10/2019

Solicitante:

MEDIMMUNE LTD [GB]
ZENYTH OPERATIONS PTY LTD [AU]

US_2019040145_A1

Resumen de: US2019309077A1

Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.

traducir

DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA

NºPublicación: EP3548004A1 09/10/2019

Solicitante:

RAY PARTHA S [US]

WO_2018102457_PA

Resumen de: WO2018102457A1

Disclosed herein is a method of screening AML patients who are unlikely to respond to or are not responsive to induction chemotherapy. The method includes detecting the expression level of FOXC1 in a sample obtained from the AML patient, and an elevated expression level indicates that the AML patient is unlikely to respond to or is not responsive to induction chemotherapy. Also disclosed herein is a method of treating AML patients who are unlikely to respond to or are not responsive to induction chemotherapy. The method includes detecting the expression level of FOXC1 in a sample obtained from the AML patient, and administering a therapeutically effective amount of one or more alternative therapies to the AML patient who has an elevated level of FOXC1 expression. The alternative therapy includes, for example, stem cell transplantation, radiotherapy, or a targeted therapy.

traducir

4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO 2, 3-B PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS

NºPublicación: WO2019185631A1 03/10/2019

Solicitante:

UNIV MASARYKOVA [CZ]

Resumen de: WO2019185631A1

The present invention relates to novel 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine compounds which are useful in the treatment of lymphomas, leukaemias, and solid tumors.

traducir

SELECTIVE ANTI-CANCER AGENT EFFECTIVE FOR PREVENTION AND TREATMENT

NºPublicación: WO2019191776A1 03/10/2019

Solicitante:

HALL JOHN L [US]
BELJANSKI SYLVIE P [US]

Resumen de: WO2019191776A1

De-ethylflavopereirine, a pharmaceutically acceptable salt thereof, a solvate or a hydrate thereof, or a pharmaceutically acceptable salt of a solvate or a hydrate thereof may be used as cancer therapy (i.e., prevention and/or treatment) in a subject in need thereof, including a pathological condition such as inflammation, especially chronic, or cancer (e.g., a carcinoma, a sarcoma, a melanoma, a leukemia, a lymphoma), especially a solid tumor and/or a metastasis thereof. In particular, systemic administration of such improved anti-cancer agents in effective amounts may selectively destroy cancer cells (including cancer stem cells) in a solid tumor and/or at a site of metastasis. They are well-tolerated by the subject, even at large systemic doses and their resulting high concentrations in the circulation, and provide safe and effective anti-cancer agents.

traducir

DOSING REGIMEN

NºPublicación: US2019298718A1 03/10/2019

Solicitante:

CYCLACEL LTD [GB]

Resumen de: US2019298718A1

The invention relates to a method of treating AML in a subject having a white blood cell (WBC) count of less than about 10,000 cells/microliter, and/or a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or the subject falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN), wherein the method comprises (i) a first treatment cycle comprising administering decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and (ii) a second treatment cycle comprising administering sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.

traducir

TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: US2019300609A1 03/10/2019

Solicitante:

AMGEN RES MUNICH GMBH [DE]

Resumen de: US2019300609A1

The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to an adult patient in the need thereof.

traducir

METHOD FOR IDENTIFYING HIGH-RISK AML PATIENTS

NºPublicación: US2019300956A1 03/10/2019

Solicitante:

UNIV HEALTH NETWORK [CA]

KR_20180107235_A

Resumen de: US2019300956A1

There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.

traducir

Genetically Modified Mice and Engraftment

NºPublicación: US2019297862A1 03/10/2019

Solicitante:

REGENERON PHARMA [US]
UNIV YALE [US]
INSTITUTE FOR RES IN BIOMEDICINE IRB [CH]

ES_2700852_T3

Resumen de: US2019297862A1

A mouse with a humanization of the miL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

traducir

COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE

NºPublicación: WO2019191032A1 03/10/2019

Solicitante:

CLEAR CREEK BIO INC [US]

US_2019292154_A1

Resumen de: WO2019191032A1

The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2'-halo-1-1'-biphenyl-4-yl)- quinoline carboxylic acids, which are useful as DHODH inhibitors.

traducir

CONSTRUCTS TARGETING CD22 AND USES THEREOF

NºPublicación: WO2019191704A1 03/10/2019

Solicitante:

EUREKA THERAPEUTICS INC [US]
CUI JUN [US]
ZHANG PENGBO [US]
XU YIYANG [US]
LI SHAN [US]
XU YIXIANG [US]
XIONG GUANGYAN [US]

Resumen de: WO2019191704A1

Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO:205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

traducir

SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF

NºPublicación: WO2019184966A1 03/10/2019

Solicitante:

SHENZHEN TARGETRX INC [CN]

Resumen de: WO2019184966A1

A substituted amino heterocyclic carboxamide compound as represent by formula (Φ), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a crystal form, a stereoisomer or an isotopic variant of the compound, and a pharmaceutical composition thereof, and the use thereof as an FLT3/AXL kinase inhibitor for treating acute myelocytic leukemia. (Φ)

traducir

OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE

Nº publicación: WO2019189732A1 03/10/2019

Solicitante:

SUMITOMO DAINIPPON PHARMA CO LTD [JP]

Resumen de: WO2019189732A1

The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, said compound inhibiting the binding of an MLL fusion protein, in which a typical fusion partner gene such as AF4 or AF9 inducing MLL leukemia is fused, to menin and thus exerting an antitumor effect. [In the formula: p represents 1 or 2; R1 represents -CF3, etc.; R2a, R2b, R3a and R3b represent a hydrogen atom, etc.; and X represents -C(=O)-, etc.]

traducir

Página1 de 3 nextPage por página

punteroimgVolver